Akers Biosciences (AKER) announced that it has completed the clinical study evaluating its PIFA/Chlamydia Rapid Assay, the first rapid test for Chlamydia diagnosis using a finger stick blood sample. Results showed that it was 91% sensitive (true positives) and 98% specific (true negatives) compared to the reference laboratory reference method. The overall concordance rate was 96%.The company intends to file a 510(k) application with the FDA as soon as feasible.